Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oral antiviral treatment

- PMLiVE

100,000 doses of Janssen’s COVID-19 delivered to Ukraine under COVAX initiative

WHO in Ukraine has trained more than 100 medical workers across the country to conduct further training on the use of Ad26.COV2-S

- PMLiVE

Pfizer and BioNTech seek FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies have rapidly increased production of the newly developed vaccine and are ready to deliver doses from September

- PMLiVE

Moderna to supply Canada with 12 million doses of Omicron-containing bivalent COVID-19 booster

The company announced in July that it was advancing two bivalent candidates for autumn, based on different population health security strategies in different countries

- PMLiVE

WHO recommends Valneva’s COVID-19 vaccine for those aged between 18 to 50 years old

VLA2001 is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine, employing a similar approach to the flu vaccine

- PMLiVE

Pfizer told by FDA to test additional Paxlovid course in patients with COVID-19 rebound

The company must produce the initial results of a randomised controlled trial by 30 September next year

- PMLiVE

NHS England reveals COVID-19 autumn booster campaign plans

The rollout will begin in early September and see Moderna’s next generation bivalent COVID-19 vaccine offered where appropriate

- PMLiVE

COVID-19 linked to higher risk of brain fog, dementia and psychosis in new study

The study also found that adults faced an increased risk of anxiety and depression, but this subsided within two months of illness

- PMLiVE

CureVac announces start of phase 1 trial of modified COVID-19 mRNA vaccine candidate

Developed in collaboration with GSK, CV0501 is specifically designed to protect against the Omicron variant

- PMLiVE

Merck and Orna agree on deal worth $3.5bn for RNA technology

The companies will work together to develop proprietary circular RNA technology

- PMLiVE

AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer

Prostate cancer is the second most common cancer in male patients in the US, projected to cause around 35,000 deaths in 2022

- PMLiVE

JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign

The programme was expanded in response to the Omicron variant to include everyone aged 50 and over

- PMLiVE

WHO releases interim statement on COVID-19 vaccination for children and adolescents

Only 25% of older populations have received a complete primary series of COVID-19 vaccines in lower income countries

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links